# Vicor Corp: financial statements, quarterly

VICR · Nasdaq · CIK 751978 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vicr.md) · [Financials](/companies/vicr/financials.md) · [Filings](/companies/vicr/filings.md) · [Insiders](/companies/vicr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vicr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [107](/filings/0000950170-24-088586.md) | [108](/filings/0000950170-24-118784.md) | [92.7 d](/filings/0001193125-26-085102.md) | [83.9](/filings/0000950170-25-060629.md) | [85.9](/filings/0000950170-25-101161.md) | [93.2](/filings/0001193125-25-256259.md) | [96.2 d](/filings/0001193125-26-085102.md) | [94.0](/filings/0001193125-26-194947.md) | [96.0](/filings/0000950170-25-101161.md) | [408](/filings/0001193125-26-085102.md) | [107 d](/filings/0001193125-26-085102.md) | [113](/filings/0001193125-26-194947.md) |
| Cost of revenue | $m | [51.6](/filings/0000950170-24-088586.md) | [52.0](/filings/0000950170-24-118784.md) | [45.3 d](/filings/0001193125-26-085102.md) | [38.7](/filings/0000950170-25-060629.md) | [43.1](/filings/0000950170-25-101161.md) | [47.4](/filings/0001193125-25-256259.md) | [45.8 d](/filings/0001193125-26-085102.md) | [49.6](/filings/0001193125-26-194947.md) | [48.9](/filings/0000950170-25-101161.md) | [46.9](/filings/0001193125-25-256259.md) | [47.8 d](/filings/0001193125-26-085102.md) | [50.6](/filings/0001193125-26-194947.md) |
| Gross profit | $m | [55.2](/filings/0000950170-24-088586.md) | [55.9](/filings/0000950170-24-118784.md) | [47.3 d](/filings/0001193125-26-085102.md) | [45.1](/filings/0000950170-25-060629.md) | [42.8](/filings/0000950170-25-101161.md) | [45.7](/filings/0001193125-25-256259.md) | [50.4 d](/filings/0001193125-26-085102.md) | [44.4](/filings/0001193125-26-194947.md) | [92.1](/filings/0000950170-25-101161.md) | [63.5](/filings/0001193125-25-256259.md) | [59.4 d](/filings/0001193125-26-085102.md) | [62.4](/filings/0001193125-26-194947.md) |
| Research and development | $m | [16.9](/filings/0000950170-24-088586.md) | [17.8](/filings/0000950170-24-118784.md) | [17.3 d](/filings/0001193125-26-085102.md) | [18.0](/filings/0000950170-25-060629.md) | [16.9](/filings/0000950170-25-101161.md) | [17.0](/filings/0001193125-25-256259.md) | [17.0 d](/filings/0001193125-26-085102.md) | [19.4](/filings/0001193125-26-194947.md) | [18.8](/filings/0000950170-25-101161.md) | [19.9](/filings/0001193125-25-256259.md) | [20.5 d](/filings/0001193125-26-085102.md) | [22.3](/filings/0001193125-26-194947.md) |
| Selling, general and administrative | $m | [20.4](/filings/0000950170-24-088586.md) | [22.4](/filings/0000950170-24-118784.md) | [22.7 d](/filings/0001193125-26-085102.md) | [26.0](/filings/0000950170-25-060629.md) | [23.3](/filings/0000950170-25-101161.md) | [23.4](/filings/0001193125-25-256259.md) | [24.2 d](/filings/0001193125-26-085102.md) | [25.1](/filings/0001193125-26-194947.md) | [28.0](/filings/0000950170-25-101161.md) | [22.7](/filings/0001193125-25-256259.md) | [23.2 d](/filings/0001193125-26-085102.md) | [23.2](/filings/0001193125-26-194947.md) |
| Operating income | $m | [17.9](/filings/0000950170-24-088586.md) | [15.7](/filings/0000950170-24-118784.md) | [7.3 d](/filings/0001193125-26-085102.md) | [(16.1)](/filings/0000950170-25-060629.md) | [0.2](/filings/0000950170-25-101161.md) | [5.4](/filings/0001193125-25-256259.md) | [9.2 d](/filings/0001193125-26-085102.md) | [(0.1)](/filings/0001193125-26-194947.md) | [45.4](/filings/0000950170-25-101161.md) | [20.9](/filings/0001193125-25-256259.md) | [15.7 d](/filings/0001193125-26-085102.md) | [16.9](/filings/0001193125-26-194947.md) |
| Income tax | $m | [2.5](/filings/0000950170-24-088586.md) | [1.0](/filings/0000950170-24-118784.md) | [1.9 d](/filings/0001193125-26-085102.md) | [1.1](/filings/0000950170-25-060629.md) | [4.2](/filings/0000950170-25-101161.md) | [(2.5)](/filings/0001193125-25-256259.md) | [1.5 d](/filings/0001193125-26-085102.md) | [0.4](/filings/0001193125-26-194947.md) | [7.8](/filings/0000950170-25-101161.md) | [(5.0)](/filings/0001193125-25-256259.md) | [(27.3) d](/filings/0001193125-26-085102.md) | [(0.3)](/filings/0001193125-26-194947.md) |
| Net income | $m | [17.1](/filings/0000950170-24-088586.md) | [16.6](/filings/0000950170-24-118784.md) | [8.7 d](/filings/0001193125-26-085102.md) | [(14.5)](/filings/0000950170-25-060629.md) | [(1.2)](/filings/0000950170-25-101161.md) | [11.6](/filings/0001193125-25-256259.md) | [10.2 d](/filings/0001193125-26-085102.md) | [2.5](/filings/0001193125-26-194947.md) | [41.2](/filings/0000950170-25-101161.md) | [28.3](/filings/0001193125-25-256259.md) | [46.5 d](/filings/0001193125-26-085102.md) | [20.7](/filings/0001193125-26-194947.md) |
| Diluted EPS | $ per share | [0.38](/filings/0000950170-24-088586.md) | [0.37](/filings/0000950170-24-118784.md) | not reported | [(0.33)](/filings/0000950170-25-060629.md) | [(0.03)](/filings/0000950170-25-101161.md) | [0.26](/filings/0001193125-25-256259.md) | not reported | [0.06](/filings/0001193125-26-194947.md) | [0.91](/filings/0000950170-25-101161.md) | [0.63](/filings/0001193125-25-256259.md) | not reported | [0.44](/filings/0001193125-26-194947.md) |
| Basic EPS | $ per share | [0.39](/filings/0000950170-24-088586.md) | [0.37](/filings/0000950170-24-118784.md) | not reported | [(0.33)](/filings/0000950170-25-060629.md) | [(0.03)](/filings/0000950170-25-101161.md) | [0.26](/filings/0001193125-25-256259.md) | not reported | [0.06](/filings/0001193125-26-194947.md) | [0.92](/filings/0000950170-25-101161.md) | [0.63](/filings/0001193125-25-256259.md) | not reported | [0.45](/filings/0001193125-26-194947.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [204](/filings/0000950170-23-038388.md) | [228](/filings/0000950170-23-058625.md) | [242](/filings/0000950170-25-030619.md) | [239](/filings/0000950170-24-051264.md) | [252](/filings/0000950170-24-088586.md) | [268](/filings/0000950170-24-118784.md) | [277](/filings/0001193125-26-085102.md) | [296](/filings/0000950170-25-060629.md) | [339](/filings/0000950170-25-101161.md) | [362](/filings/0001193125-25-256259.md) | [403](/filings/0001193125-26-194947.md) | [404](/filings/0001193125-26-194947.md) |
| Current assets | $m | [379](/filings/0000950170-23-038388.md) | [399](/filings/0000950170-23-058625.md) | [420](/filings/0000950170-25-030619.md) | [428](/filings/0000950170-24-051264.md) | [435](/filings/0000950170-24-088586.md) | [451](/filings/0000950170-24-118784.md) | [463](/filings/0001193125-26-085102.md) | [487](/filings/0000950170-25-060629.md) | [515](/filings/0000950170-25-101161.md) | [534](/filings/0001193125-25-256259.md) | [587](/filings/0001193125-26-194947.md) | [599](/filings/0001193125-26-194947.md) |
| Total assets | $m | [561](/filings/0000950170-23-038388.md) | [584](/filings/0000950170-23-058625.md) | [595](/filings/0000950170-25-030619.md) | [605](/filings/0000950170-24-051264.md) | [613](/filings/0000950170-24-088586.md) | [633](/filings/0000950170-24-118784.md) | [641](/filings/0001193125-26-085102.md) | [665](/filings/0000950170-25-060629.md) | [694](/filings/0000950170-25-101161.md) | [710](/filings/0001193125-25-256259.md) | [786](/filings/0001193125-26-194947.md) | [805](/filings/0001193125-26-194947.md) |
| Current liabilities | $m | [50.0](/filings/0000950170-23-038388.md) | [46.5](/filings/0000950170-23-058625.md) | [44.2](/filings/0000950170-25-030619.md) | [64.1](/filings/0000950170-24-051264.md) | [67.8](/filings/0000950170-24-088586.md) | [70.4](/filings/0000950170-24-118784.md) | [61.8](/filings/0001193125-26-085102.md) | [75.7](/filings/0000950170-25-060629.md) | [73.8](/filings/0000950170-25-101161.md) | [70.7](/filings/0001193125-25-256259.md) | [65.3](/filings/0001193125-26-194947.md) | [41.9](/filings/0001193125-26-194947.md) |
| Total liabilities | $m | [59.6](/filings/0000950170-23-038388.md) | [55.4](/filings/0000950170-23-058625.md) | [53.8](/filings/0000950170-25-030619.md) | [73.1](/filings/0000950170-24-051264.md) | [75.8](/filings/0000950170-24-088586.md) | [77.9](/filings/0000950170-24-118784.md) | [70.8](/filings/0001193125-26-085102.md) | [84.5](/filings/0000950170-25-060629.md) | [84.6](/filings/0000950170-25-101161.md) | [79.9](/filings/0001193125-25-256259.md) | [74.0](/filings/0001193125-26-194947.md) | [50.8](/filings/0001193125-26-194947.md) |
| Shareholders' equity | $m | [501](/filings/0000950170-23-038388.md) | [529](/filings/0000950170-23-058625.md) | [541](/filings/0000950170-25-030619.md) | [532](/filings/0000950170-24-051264.md) | [537](/filings/0000950170-24-088586.md) | [555](/filings/0000950170-24-118784.md) | [570](/filings/0001193125-26-085102.md) | [580](/filings/0000950170-25-060629.md) | [609](/filings/0000950170-25-101161.md) | [630](/filings/0001193125-25-256259.md) | [712](/filings/0001193125-26-194947.md) | [754](/filings/0001193125-26-194947.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [19.0 d](/filings/0000950170-24-088586.md) | [23.8 d](/filings/0000950170-24-118784.md) | [21.5 d](/filings/0001193125-26-085102.md) | [2.6](/filings/0000950170-25-060629.md) | [15.6 d](/filings/0000950170-25-101161.md) | [22.6 d](/filings/0001193125-25-256259.md) | [10.1 d](/filings/0001193125-26-085102.md) | [20.1](/filings/0001193125-26-194947.md) | [65.2 d](/filings/0000950170-25-101161.md) | [38.5 d](/filings/0001193125-25-256259.md) | [15.7 d](/filings/0001193125-26-085102.md) | [(3.9)](/filings/0001193125-26-194947.md) |
| Capital expenditure | $m | [8.5 d](/filings/0000950170-24-088586.md) | [7.7 d](/filings/0000950170-24-118784.md) | [7.2 d](/filings/0001193125-26-085102.md) | [7.3](/filings/0000950170-25-060629.md) | [6.1 d](/filings/0000950170-25-101161.md) | [8.5 d](/filings/0001193125-25-256259.md) | [1.7 d](/filings/0001193125-26-085102.md) | [4.6](/filings/0001193125-26-194947.md) | [6.2 d](/filings/0000950170-25-101161.md) | [4.0 d](/filings/0001193125-25-256259.md) | [5.5 d](/filings/0001193125-26-085102.md) | [12.4](/filings/0001193125-26-194947.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [0.5 d](/filings/0001193125-25-256259.md) | [0.0 d](/filings/0001193125-26-085102.md) | not reported | not reported | [15.4 d](/filings/0001193125-25-256259.md) | [2.2 d](/filings/0001193125-26-085102.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [44.9](/filings/0000950170-23-038388.md) | [44.9](/filings/0000950170-23-058625.md) | [44.9](/filings/0000950170-24-051264.md) | [44.9](/filings/0000950170-24-088586.md) | [45.2](/filings/0000950170-24-118784.md) | [44.5](/filings/0000950170-25-060629.md) | [44.9](/filings/0000950170-25-101161.md) | [45.2](/filings/0001193125-25-256259.md) | [45.5](/filings/0001193125-26-194947.md) | [45.1](/filings/0000950170-25-101161.md) | [44.9](/filings/0001193125-25-256259.md) | [47.3](/filings/0001193125-26-194947.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,978,949 at 2015-04-24, from the cover of the [10-Q filed 2015-04-30](/filings/0001193125-15-161080.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.